Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Amneal beat quarterly estimates: Revenue rose 10% to $862.7 million, adjusted EPS increased 53% to $0.26 versus the $0.23 consensus, and adjusted EBITDA climbed 30% to $207 million. The company also raised its 2026 revenue, EBITDA, and EPS guidance.
• Growth initiatives are gaining traction: Affordable medicines revenue rose 19% to $547 million, lanreotide sales reached about $7 million shortly after launch, and specialty products CREXONT and BREKIYA continued to exceed expectations. The Kashiv acquisition is expected to generate $400 million–$500 million in long-term financial benefits.
• Cash flow and leverage remain concerns: Amneal reduced operating cash flow guidance because of inventory investments and delayed collections, while net leverage is expected to increase to 3.6 times adjusted EBITDA by year-end. Analysts remain broadly positive, with a “Moderate Buy” consensus rating and an average price target of $22.86.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) announced its earnings results on Tuesday. The company reported $0.26 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.03, FiscalAI reports. The business had revenue of $862.68 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%.

Here are the key takeaways from Amneal Pharmaceuticals' conference call:

• Strong Q3 performance: Revenue rose 10% to $863 million, adjusted EBITDA increased 30% to $207 million, and adjusted EPS grew 53% to $0.26, prompting Amneal to raise its 2026 revenue, EBITDA, and EPS guidance.
• Affordable medicines revenue increased 19% to $547 million, supported by women’s health transdermal patches, new product launches, and biosimilar orders. The recently launched lanreotide generated approximately $7 million in late-September sales, with management expecting substantially higher revenue in Q4 and targeting 30%–40% market share.
• The completed Kashiv acquisition gives Amneal integrated biosimilar development, manufacturing, and commercialization capabilities. Management expects $400 million–$500 million of financial benefits over time and recently secured $60 million in New Jersey tax credits tied largely to biosimilar-related expansion.
• Specialty products continued to gain momentum, with CREXONT adding approximately 400 prescribers monthly and BREKIYA tracking ahead of expectations. Management expressed confidence that both products could reach the middle to high end of its long-term outlook.
• Operating cash flow guidance was reduced by $25 million at the midpoint to $325 million–$375 million because Amneal is building finished-goods inventory to meet demand and expects some collections to shift into Q1 2027. Net leverage was 3.0 times adjusted EBITDA after the Kashiv acquisition, with year-end leverage expected to rise to 3.6 times.

Amneal Pharmaceuticals Trading Down 0.6%

Shares of Amneal Pharmaceuticals stock traded down $0.12 during mid-day trading on Tuesday, hitting $20.32. 377,763 shares of the stock were exchanged, compared to its average volume of 2,382,516. Amneal Pharmaceuticals has a twelve month low of $10.92 and a twelve month high of $21.68. The stock has a market capitalization of $6.49 billion, a price-to-earnings ratio of 41.48, a price-to-earnings-growth ratio of 2.46 and a beta of 1.22. The company has a 50-day simple moving average of $19.17 and a 200 day simple moving average of $15.78. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AMRX. JPMorgan Chase & Co. lifted their price objective on Amneal Pharmaceuticals from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Thursday, October 22nd. Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, July 12th. Zacks Research raised Amneal Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday, October 26th. Leerink Partners assumed coverage on Amneal Pharmaceuticals in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $23.00 price target on the stock. Finally, Oppenheimer began coverage on Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They set an "outperform" rating and a $27.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $22.86.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director John Kiely sold 50,000 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the transaction, the director owned 210,252 shares of the company's stock, valued at $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the transaction, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 413,016 shares of company stock worth $7,216,567 over the last ninety days. 17.30% of the stock is currently owned by corporate insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company's generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.